Iovance Biotherapeutics, Inc. (IOVA)
Health Care ยท Biological Products, (No Diagnostic Substances)
Iovance Biotherapeutics, Inc. (IOVA) is listed on Nasdaq, where its shares have traded since May 26, 2010. SentiSense covers Iovance Biotherapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Frederick Vogt is its chief executive officer. The company reports 975 employees, and its corporate website is www.iovance.com.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 280 institutions reported holding IOVA, with 285.2 million shares worth $1.2 billion in aggregate. The largest reported holders were BlackRock, Vanguard and Mhr Fund Management. Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter.
More on IOVA
- IOVA sentiment: whether news and social coverage of Iovance Biotherapeutics, Inc. leans bullish or bearish, and the stories driving it.
- IOVA ownership: all 280 reporting institutions, plus insider and congressional trades.
- IOVA financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Iovance Biotherapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Iovance Biotherapeutics, Inc. do?
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient.
What sector is IOVA in?
SentiSense classifies Iovance Biotherapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does IOVA stock trade?
Iovance Biotherapeutics, Inc. (IOVA) is listed on Nasdaq, where its shares have traded since May 26, 2010.
Who is the CEO of Iovance Biotherapeutics, Inc.?
Frederick Vogt is the chief executive officer of Iovance Biotherapeutics, Inc..